The ‘Re-Pricer’ Reckoning: Makena, Daraprim And Acthar Under Pressure
Executive Summary
The controversies have shown that, while it may be easy to scapegoat outliers, it is remarkably hard to lower a drug price by political fiat. It took a while, but now Makena, Daraprim and Acthar are all facing very different days of reckoning.
You may also be interested in...
Medicaid Rebate Suit Focuses On FDA Approval Status Of Acthar's New Indication
US government says Mallinckrodt avoided millions in Medicaid rebates by claiming Acthar’s added indication was approved as a new NDA rather than a supplemental application.
Daraprim Drug Pricing Suit Against Shkreli And Vyera May Signal Future FTC Actions
In joint complaint, the FTC and New York Attorney General allege scheme to block generic Daraprim and maintain exorbitant list price; they cite hundreds of emails the incarcerated Shkreli has exchanged with co-defendant in last six months.
Makena Withdrawal Dilemma: Advisory Cmte. Split Offers No Clear Direction For US FDA
Nine of 16 advisory committee members favored withdrawal of AMAG’s preterm birth drug because substantial evidence of efficacy is lacking and clinical benefit has not been confirmed; seven panelists favored keeping the drug on the market but requiring a new trial.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: